Actinium Pharmaceuticals (Delaware) (ATNM) vs Filana Therapeutics (FLNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed Filana Therapeutics (FLNA) over the past year, losing 26.7% versus a loss of 80.5%. Over five years, ATNM leads with a -86.3% price change compared with -98.4% for FLNA. Filana Therapeutics is the larger company by market cap ($39.5 million vs $34.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | FLNA |
|---|---|---|
| Share price | $1.10 | $0.8168 |
| Market cap | $34.59M | $39.46M |
| 1-day change | +1.85% | +0.39% |
| YTD return | -19.12% | -58.75% |
| 1-year return | -26.67% | -80.51% |
| 5-year return | -86.32% | -98.36% |
| P/E ratio (TTM) | 3.06 | — |
| EPS (TTM) | $0.36 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.74 | $4.98 |
| 52-week low | $0.735 | $0.67 |
| Distance from 52-week high | -36.78% | -83.60% |
| Analyst consensus | none | none |
| Avg. price target upside | +227.27% | +695.79% |
| Average volume | 139.78K | 2.05M |
| Shares outstanding | 31.44M | 48.31M |
| Employees | 27 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATNM has outperformed FLNA by 53.8 percentage points over the past year.
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Filana Therapeutics
FLNA stock →Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
ATNM vs FLNA FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or Filana Therapeutics?
Filana Therapeutics (FLNA) is larger, with a market capitalization of $39.46M compared with $34.59M for Actinium Pharmaceuticals (Delaware) (ATNM).
Which stock has performed better over the past year, ATNM or FLNA?
ATNM returned -26.67% over the past 12 months, compared with -80.51% for FLNA (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and Filana Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.